February 8, 2024 04:31 AM ESTUpdated 06:40 AM
Financing
Startups
Cell/Gene Tx

Kyver­na lands $319M IPO as au­toim­mune CAR-T field has its mo­ment in the sun

Kyle LaHucik

Senior Reporter

Cal­i­for­nia biotech Kyver­na Ther­a­peu­tics will gar­ner $319 mil­lion from its Thurs­day morn­ing Nas­daq de­but as it rides a small but wel­come wave of in­vestor en­thu­si­asm …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times